[HTML][HTML] Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer

SL Zhang, YQ Mao, ZY Zhang, ZM Li, CY Kong… - Theranostics, 2021 - ncbi.nlm.nih.gov
Background: Anti-PD-1-based immunotherapy has emerged as a promising therapy for
several cancers. However, it only benefits a small subset of colorectal cancer (CRC) …

Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer

Z Shi-Long, M Yu-Qin, Z Zheng-Yan… - …, 2021 - search.proquest.com
Background: Anti-PD-1-based immunotherapy has emerged as a promising therapy for
several cancers. However, it only benefits a small subset of colorectal cancer (CRC) …

Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer

SL Zhang, YQ Mao, ZY Zhang, ZM Li… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background: Anti-PD-1-based immunotherapy has emerged as a promising therapy for
several cancers. However, it only benefits a small subset of colorectal cancer (CRC) …

Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.

SL Zhang, YQ Mao, ZY Zhang, ZM Li, CY Kong… - Theranostics, 2021 - europepmc.org
Background: Anti-PD-1-based immunotherapy has emerged as a promising therapy for
several cancers. However, it only benefits a small subset of colorectal cancer (CRC) …

[PDF][PDF] Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer

pdfs.semanticscholar.org
Abstract Background: Anti-PD-1-based immunotherapy has emerged as a promising therapy
for several cancers. However, it only benefits a small subset of colorectal cancer (CRC) …

Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.

SL Zhang, YQ Mao, ZY Zhang, ZM Li, CY Kong… - Theranostics, 2021 - europepmc.org
Background: Anti-PD-1-based immunotherapy has emerged as a promising therapy for
several cancers. However, it only benefits a small subset of colorectal cancer (CRC) …